Extreme Networks Analyst Starts Coverage with Optimism; Check Out the Top 5 Initiations for Wednesday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2025
0mins
Source: Benzinga
Analyst Ratings Overview: Top Wall Street analysts have recently changed their outlook on several companies, providing new ratings and price targets.
Rapport Therapeutics Inc: BTIG analyst Kambiz Yazdi initiated coverage with a Buy rating and a price target of $47, while shares closed at $27.01.
Riot Platforms Inc: Citizens analyst Greg Miller initiated coverage with a Market Outperform rating and a price target of $25, with shares closing at $13.42.
Extreme Networks Inc and Others: B of A Securities and Canaccord Genuity also initiated coverage on Extreme Networks and Insight Enterprises, respectively, with price targets of $24 and $100, while UBS rated Parsons Corp with a Buy and a target of $107.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like RAPP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on RAPP
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 54.60 USD with a low forecast of 40.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.440
Low
40.00
Averages
54.60
High
80.00
Current: 26.440
Low
40.00
Averages
54.60
High
80.00
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials
- FDA Approval: Rapport Therapeutics has received FDA clearance to advance RAP-219 into registrational trials, with plans to initiate its Phase 3 program in focal onset seizures in Q2 2026, marking a significant advancement in the epilepsy treatment landscape.
- Clinical Data Support: The robust Phase 2a data positions RAP-219 as a potential best-in-class therapy, aimed at addressing the limitations of current treatments in tolerability and efficacy, thereby fulfilling a critical unmet need for patients.
- Multicenter Trial Design: The Phase 3 trial will be a multicenter, randomized, double-blind study enrolling adults, focusing on seizure frequency reduction and long-term safety, which is expected to lay the groundwork for future market introduction.
- Sufficient Funding: As of the third quarter, Rapport reported $531 million in cash and short-term investments, providing ample resources to fund operations into the second half of 2029, ensuring ongoing investment in R&D and market expansion.
Continue Reading
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million
- Share Increase: Cormorant Asset Management disclosed a purchase of 251,600 additional shares of Rapport Therapeutics in its SEC filing on November 14, 2025, bringing its total holdings to 3,192,521 shares valued at approximately $94.82 million, indicating a bullish outlook on the biotech firm.
- Asset Management Scale: This increase positions Rapport as 6.54% of Cormorant's 13F assets under management, reflecting the firm's investment strategy in the biopharmaceutical sector and confidence in future growth prospects.
- Market Performance: As of November 14, 2025, Rapport Therapeutics shares were priced at $24.37, up 10.87% over the past year, although slightly underperforming the S&P 500, highlighting market interest in its potential drug candidates.
- Financial Status: Despite reporting a net loss of $26.9 million in Q3, Rapport holds $513 million in cash and short-term investments, expected to sustain operations into the second half of 2029, indicating ongoing commitment to research and development.
Continue Reading